Ì«Ñô¼¯ÍŹÙÍø

English Ì«Ñô¼¯ÍŹÙÍø¼¯ÍÅÆóÒµÓÊÏä

ʪÈóÉÕÉ˸àÖÎÁÆÖØÖ¢ÈÕ¹âÆ¤Ñ×ÁÙ´²ÊÓ²ì

2013Äê-06ÔÂ-24ÈÕ ÈªÔ´£ºÌ«Ñô¼¯ÍŹÙÍø¹ú¼Ê¼¯ÍÅ

¹ãÎ÷±±º£ÊÐÖÐÒ½Ôº  ¬ҵÐù
 

¡¾ÕªÒª¡¿Ä¿µÄ  ÊÓ²ìʪÈóÉÕÉ˸ࣨMEBO£©ÖÎÁÆÖØÖ¢ÈÕ¹âÆ¤Ñ×µÄÁÆÐ§¡£ÒªÁì  Æ¾Ö¤»¼ÕßËù½ÓÊܵÄÖÎÁÆÒªÁ죬°Ñ47ÀýÖØÖ¢ÈÕ¹âÆ¤Ñ׵ϼÕß·ÖΪ2×éÖÎÁÆ¡£ÖÎÁÆ×é28Àý£¬È«³ÌͨÀýÓ¦ÓÃMEBOÍâÖΣ»±ÈÕÕ×é19Àý£¬È«³ÌÓ¦ÓõØÈûÃ×ËÉÈé¸àÍâÖΣ¬ÁƳ̾ùΪ4 d¡£Ð§¹û  2×éÁÆÐ§ÓÐÏÔÖø²î±ð£¬ÖÎÁÆ×éÓÅÓÚ±ÈÕÕ×é¡£½áÂÛ  MEBO¶ÔÖØÖ¢ÈÕ¹âÆ¤Ñ×¾ßÓÐÓÅÒìµÄÖÎÁÆ×÷Óá£
¡¾Òªº¦´Ê¡¿MEBO£»ÈÕ¹âÆ¤Ñ×£»µØÈûÃ×ËÉ
¡¾Abstract¡¿Objective To observe the therapeutic effect of MEBO Wound Ointment £¨MEBO£©in the treatment of severe solar dermatitis. Method The  47 patients with severe solar dermatitis were randomly grouped into treatment group (28 cases) in which the topical administration of MEBO Wound Ointment was given routinely for the entire treating process and control group (19 cases) in which the Dexamethasone ointment was topically administered routinely for the whole treating process. The treating process of both groups was four days. Results The therapeutic effects of both groups had significant difference with the treatment group superior to control group. Conclusion MEBO Wound Ointment has good therapeutic effect in the treatment of severe solar dermatitis.
¡¾Key words¡¿MEBO; Dermatitis£»Dexamethasone
¡¡¡¡ÈÕ¹âÆ¤Ñ×ÓÖÃûɹ°ß£¬¶à±¬·¢ÓÚ´ºÄ©¼°Ñ×Ìì¡£ÇáÕß»¼´¦Ö»Óкì°ß×ÆÍ´£¬ÖØÕߺì°ßÑÕÉ«¼ÓÉ°éÓÐË®Öס¢Ë®ðå»ò´óðå×ÆÍ´[1]¡£±¾ÎÄËùÑ¡µÄ²¡Àý£¬ÈªÔ´ÓÚ2005Äê5ÔÂÖÁ2010Äê7Ô¼äÊÕÖεÄÃÅÕﲡÀý£¬¾ùϵϺ£ÓÎÓ¾»ò¼ÓÈë¾üѵ£¬Æ¤·ô̻¶±»¾Ãɹ¶øÖµÄ֢֨ɹÉË»¼Õß¡£
1.ÁÙ´²×ÊÁÏ
1.1.Ò»Ñùƽ³£×ÊÁÏ
¡¡¡¡¶ÔÒÑÍùÖÎÁƵÄ47ÀýÖØÖ¢ÈÕ¹âÆ¤Ñײ¡Àú×ÊÁϾÙÐлØÊ×ÐÔÆÊÎö¡£ÆäÖнÓÄÉʪÈóÉÕÉ˸àÖÎÁÆÕß28Àý£¬Î½Ö®ÖÎÁÆ×飻ÆäÓàΪ±ÈÕÕ×飨19Àý£©¡£ÖÎÁÆ×éÄÐ15Àý£¬Å®13Àý£¬ÄêËê16Ëê~25Ë꣬ƽ¾ùƤËðÃæ»ý£¨²ÎÕÕÖйú¾Å·Ö·¨ÅÌË㣩Ϊ18%TBSA£»±ÈÕÕ×éÄÐ10Àý£¬Å®9Àý£¬ÄêËê17Ëê~24Ë꣬ƽ¾ùƤËðÃæ»ýΪ16.5%TBSA¡£
1.2.ÖÎÁÆÒªÁì
¡¡¡¡Á½×黼ÕßÓÃҩǰ¾ùÓڽϺéÁ÷ðåµÄµÍλ²¿¼ôÆÆ·ÅË®£¬±£´æð寤ÖÁµÚ3 dºóìî³ý¡£ÖÎÁÆ×é²ÎÕÕdz¢ò¶ÈÉÕÉ˵Ĵ¦Öóͷ£ÒªÁì[2]ÍâÍ¿MEBO£¬ºñ¶È±¡ÓÚ1 mm£¬Ã¿6 h»»Ò©1´Î¡£±ÈÕÕ×é¾­ÀäÐÄÀíÑÎË®Çå½à´´Ãæºó£¬ÍâÍ¿Èý¾ÅƤÑׯ½£¨µØÈûÃ×ËÉ£©Èé¸à£¬ºñ¶È±¡ÓÚ1 mm£¬ÌìÌì»»Ò©3´Î£¬ÁƳ̾ùΪ4 d¡£
1.3.ÁÆÐ§±ê×¼£¨×ÔÄ⣩
¡¡¡¡È¬Óú£ººì°ßË®Ö×ÏûÍË£¬Æ¤ËðÓúºÏ£¬Í´Ö¢Ïû³ý£»ºÃת£ººì°ßË®Ö×ÏûÍË£¬Í´Ö¢Ïû³ý£¬Æ¤ËðδÍêÈ«ÓúºÏ£»ÎÞЧ£ºÆ¤ËðÎÞÏÔןÄÉÆ¡£
2.Ч¹û
¡¡¡¡ÖÎÁÆ×éȬÓú25Àý£¬ºÃת3Àý£¬ËùÓÐÓÐÓã¬ÖÎÓúÂÊΪ89.29%£»±ÈÕÕ×éȬÓú11Àý£¬ºÃת8Àý£¬ËùÓÐÓÐÓã¬ÖÎÓúÂÊΪ57.89%¡£¾­ÓÃËĸñ±íχ2ֵУÕýÄ¥Á·£¬Á½×éÁÆÐ§ÓÐÏÔÖø²î±ð£¬ÖÎÁÆ×éÓÅÓÚ±ÈÕÕ×飬P<0.05¡£
3.ÌÖÂÛ
¡¡¡¡ÖÐÒ½³ÆÈÕ¹âÆ¤Ñ×ΪÈÕɹ´¯£¬ÊÇÒò»úÌåÙ÷¸³²»ÄÍ£¬ëíÀí²»ÃÜ£¬¹â¶¾Èȶ¾ÇÖÏ®£¬ÈȲ»¹ýй£¬ÓôÓÚ¼¡·ôËùÖÂ[3]¡£ÖØÖ¢Õß»¼´¦Ñª¹ÜÀ©ÕÅ£¬Ï¸°û½þÈóË®Ö×£¬±íƤËðÉË£¬ÕæÆ¤¸Ä±ä¡£ÁÙ´²ÌåÏÖÀàËÆÇ³¢ò¶ÈÉÕÉË£¬¹ÊÎâÖ¾»ªµÈ[1]Ö÷ÕŲÎÕÕ¢ò¶ÈÈÈÉÕÉËÖÎÁÆ¡£
¡¡¡¡MEBOÓÉ»ÆÜË¡¢»Æ°Ø¡¢»ÆÁ¬¡¢·äÀ¯¡¢ÂéÓ͵ÈÖÆ³É£¬ÊÇÖÎÁÆÉÕ¡¢ÌÌ¡¢×ÆÉ˵ÄÁ¼Ò©¡£MEBOÄܹ»ÇåÈȽⶾ£¬É¨³ý΢Ѫ¹Ü¾·ÂΣ¬¸ÄÉÆÎ¢Ñ­»·£¬±£»¤´´Ãæ¼°Éñ¾­Ä©ÉÒ£¬Ïû³ýÌÛÍ´£¬»¹Äܹ»ÎüÊÕ´´ÃæÓàÈÈ£¬ÒýÈÈÍâ³ö£¬ïÔÌ­¾ÙÐÐÐÔÈÈË𣬲¢ÇÒ¿ÉÒÔÒÖ¾ú¿¹¾ú£¬¿¹Ñ×ÏûÑ×£¬Òº»¯É¨³ý»µËÀ×éÖ¯£¬Ôö½ø×é֯ϸ°ûÔÙÉú[4]¡£¹ÊÈÕ¹âÆ¤Ñ×»¼ÕßÓ¦ÓøÃÒ©ºó£¬¾­Âçͨ£¬ëíÀí³©£¬ÓàÈÈÇ壬¹â¶¾½â£¬ÌÛÍ´Ö¹£¬Ñ×Ö¢Ïû£¬Ë®Ö×ÍË£¬¸¯Èâìм¡Éú£¬±íƤºÏ¶øÈ«Óú¡£
¡¡¡¡µØÈûÃ×ËÉÈé¸àËäÄÜÏûÑ׽ⶾ£¬ÏûÖ×ֹʹ£¬µ«Ã»ÓÐìÉú¼¡Ö®¹¦Ð§£¬¹ÊÁÆÐ§½Ï²î¡£¶Ô±¾ÁÆ·¨ÖÎÁƺóδÓúºÏµÄ´´Ã棬¿É¸ÄÓÃMEBO¼ÌÐøÖÎÁÆ¡£
¡¡¡¡±¾×éËùÓв¡ÀýµÄÈ«ÉíÖ¢×´¾ù½ÏÇᣬ²»ÐèÄÚÖΣ¬µ«Ó¦ÖöÆä¼á³ÖÇå½à£¬Çåµ­Òûʳ£¬ÒõÁ¹ÐÝÏ¢,¶Ô¸ÄÉÆ²¡×´´óÓÐñÔÒæ¡£
²Î¿¼ÎÄÏ×
[1]ÎâÖ¾»ª£¬·®ÒîÃ÷£¬³ÂºìÇ壬µÈ. ÏÖ´úƤ·ôÐÔ²¡Ñ§[M]. ¹ã¶«£º¹ã¶«ÈËÃñ³öÊéÉ磬2000£º682.
[2]ÐìÈÙÏ飬ФĦ£¬¼ÍÏþ·å£¬µÈ. ÉÕÉËÆ¤·ôÔÙÉúÒ½ÁÆÊÖÒÕÁÙ´²ÊÖ²á[M]. ±±¾©£ºÖйúÒ½Ò©¿Æ¼¼³öÊéÉ磬2003£º29£¬33~35.
[3]ÈÙÕ×ÓÑ£¬ËÎÇå¾²£¬³ÌÐËÍú£¬µÈ. ÖÐҽƤ·ô¿ÆÁÙ´²ÊÖ²á[M]. ±±¾©£ºÈËÃñÎÀÉú³öÊéÉ磬1996£º253.
[4]ÐìÈÙÏ飬ФĦ£¬¼ÍÏþ·å£¬µÈ. ÉÕÉËÆ¤·ôÔÙÉúÒ½ÁÆÊÖÒÕÁÙ´²ÊÖ²á[M]. ±±¾©£ºÖйúÒ½Ò©¿Æ¼¼³öÊéÉ磬2003£º27£¬52£¬54.

ÍøÕ¾µØÍ¼